Abstract Body

Presentation:

Progress in the HIV response today depends on more than ever of use of rich toolbox of efficacious interventions (e.g., PrEP) with reach, equity, sustainability and quality in the real world. One source reason for existing gaps between identifying efficacious interventions and their use is the is traditional scientific sequence of first efficacy, then effectiveness and finally implementation trials. Hybrid trial designs – studies that seek to study both implementation as well as effectiveness simultaneously – offer important but incompletely realized opportunities to accelerate translational impact. The talk will cover current nomenclature and classification of hybrid trial types (e.g., ‘Type 1’), highlight current evolution in design and distill key insights that aim to have immediate implications for researchers conducting trials in HIV. In addition, however, I will turn attention to challenges inherent in hybrid designs that seek simultaneous investigation of implementation and clinical outcomes that are to date inadequately addressed. First, current literature in does not fully consider when and how different implementation strategies change observed subsequent clinical effects. I offer principles to help guide determination of relative importance of implementation vs. effectiveness outcomes and the plausibility of their heterogenous effects across settings or populations. Second, hybrid designs have not fully addressed unanticipated ‘adverse’ effects of implementation. The talk will therefore offer a typology of adverse effects from implementation strategies and ways researchers can capture such effects. Third, literature does not fully explore the role of implementation outcomes act as mediators of the effects of strategies on service delivery or clinical outcomes. I draw from modern epidemiological methods in mediation to highlight opportunities and pitfalls for analysis of hybrid trials, including potential utility of sequential randomization. Looking forward, I suggest that the next generation of hybrid designs can be improved by use of a causal or explanatory theory of how implementation strategies work and that use of causal diagrams can help to surface these mechanistic relationships. Throughout, I illustrate methodological principles with substantive issues importance to HIV field, such as long-acting injectable medications, differentiated service delivery models, HIV self-testing and other areas of contemporary importance.